Efficacy and Safety of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction: Systematic Review
ESC Heart Failure · 2023
DOI: 10.1002/ehf2.14473 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Juan Máximo Molina-Linde und 4 weiteren Autor:innen. Beteiligte Einrichtung: Health Technology Assessment Area-AETSA, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain. Hauptthemen laut MEDLINE: Baroreflex, Heart Failure, Stroke Volume. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Spanish Ministry of Health, Ministerio de Sanidad, Política Social e Igualdad.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Baroreflex activation therapy (BAT) is a possible adjuvant treatment for patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal medical therapy and may be an alternative therapy in patients with contraindications or drug intolerance. Our aim was to evaluate the efficacy and safety of BAT in patients with HFrEF. The protocol for this study was registered with PROSPERO (CRD42022349175). Searches were conducted using MEDLINE, preMedLine (via PubMed), EMBASE, Cochrane Library, Web of Science, Trip Medical Database, WHO International Clinical Trials Registry, and ClinicalTrials.gov. We included randomized controlled trials that compared the effects of BAT with pharmacological treatment. We assessed the risk of bias of each study using the Cochrane RoB2 tool and the certainty of the results using the GRADE approach. We performed a meta-analysis of treatment effects using a fixed-effects or random-effects model, depending on the heterogeneity observed. Two studies were included in the meta-analysis (HOPE4HF and BeAT-HF). The results showed that BAT led to statistically significant improvements in New York Heart Association functional class (relative risk 2.13; 95% confidence interval [CI, 1.65 to 2.76]), quality of life (difference in means −16.97; 95% CI [−21.87 to −12.07]), 6 min walk test (difference in means 56.54; 95% CI [55.67 to 57.41]) and N-terminal probrain natriuretic peptide (difference in means −120.02; 95% CI [−193.58 to −46.45]). The system- and procedure-related complication event-free rate varied from 85.9% to 97%. The results show that BAT is safe and improves functional class, quality of life and congestion in selected patients with HFrEF. Further studies and long-term follow-up are needed to assess efficacy in reducing cardiovascular events and mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Technology Assessment Area-AETSA, Andalusian Public Foundation Progress and Health-FPS, Seville, Spain.
- Heart Failure and Cardiomyopathy Unit, Cardiology Service Ramón y Cajal Hospital, Madrid, Spain.
- Epidemiologist at Seville Primary Care Health District, Seville, Spain.
ORCID-Profile: Juan Máximo Molina-Linde
Förderung
- Spanish Ministry of Health
- Ministerio de Sanidad, Política Social e Igualdad
Zitieren
APA
Molina-Linde, J. M., Cordero-Pereda, D., Baños-Álvarez, E., Rosario-Lozano, M. P., & Blasco-Amaro, J. A. (2023). Efficacy and Safety of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction: Systematic Review. ESC Heart Failure. https://doi.org/10.1002/ehf2.14473
Vancouver
Molina-Linde JM, Cordero-Pereda D, Baños-Álvarez E, Rosario-Lozano MP, Blasco-Amaro JA. Efficacy and Safety of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction: Systematic Review. ESC Heart Failure. 2023. doi:10.1002/ehf2.14473
BibTeX
@article{MolinaLinde2023,
author = {Molina-Linde, Juan Máximo and Cordero-Pereda, David and Baños-Álvarez, Elena and Rosario-Lozano, Maria Piedad and Blasco-Amaro, Juan Antonio},
title = {Efficacy and Safety of Baroreflex Activation Therapy for Heart Failure with Reduced Ejection Fraction: Systematic Review},
journal = {ESC Heart Failure},
year = {2023},
doi = {10.1002/ehf2.14473}
}
EUVIMED